In September, Liberty became the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot says its system aims to advance robotics without the constraints of capital equipment and a dedicated infrastructure.

Hingham, Massachusetts-based Microbot designed the Liberty robot to democratize endovascular interventional procedures. The company says it’s the world’s first single-use, fully disposable robotic system for those procedures.

Since clearance, Microbot has boosted its commercialization efforts with significant funding. The company exercised certain investment options worth up to $92.2 million last month to support the Liberty rollout. It also partnered with a third-party logistics company to support its Liberty launch the following week.